[ad_1]
A Palestinian PhD student from the UK School of Medicine has developed the persistence of Khatib, new drug compounds that act on neurons and improve their performance in different ways, in order to help patients with the disease. ; Alzheimer's.
The Khatib research team and scientific team are trying to find a cure for neurological diseases, especially Alzheimer's disease, to which scientists had until now present not found the treatment. All drugs available on the market are limited to relieve the symptoms of chronic disease.
"During my doctoral studies in Great Britain and as a researcher in the postdoctoral fellowship program at the College of Medicine in Great Britain, I studied brain and nerve cells and how they functioned in a normal situation. brain and nerve cells and changes in neurological diseases.And then tried to apply this knowledge to connect them to the soil using different techniques to find treatments to patients with neurological diseases.
"I am currently working with my research team to produce the second patent, for the development of new compounds, which we began to discover by observing a retinoic acid deficiency in animal models genetically engineered to become disease. Alzheimer's The body receives this substance and is usually derived from vitamin A from the diet.It can not manufacture it itself. "
A group of students under the supervision of Dr. Khatib
"We first tried to use retinoic acid as a treatment, but this substance was also unstable and toxic when used in high concentrations." To solve this problem, we have created retinoic acid-like compounds, synthetic retinoids are more potent and more effective, Small, these pharmaceutical compounds are still in the laboratory study to see the long-term effects. "
Al-Khatib explained that she and her team had recorded in the laboratory the results of the experiment of these compounds on the neurons, after treating the cells and found that the neurotransmitters had increased and significantly increased, then treated the genetic modifications of a group of genes associated with Alzheimer's disease. Vehicles – designed with the help of different techniques – to determine the cellular pathway responsible for these properties, and have studied the different characteristics of the compounds and their differences, such as the identification of one of the compounds able to control the expression of the gene or to control the phosphorylation of proteins (addition of phosphate to a protein) or the control of the translation of a specific part of the AMPA protein which plays an important role in the memory.
Khatib has used a range of techniques in his research, including Western blot, ELIZA, qPCR, gene modification using CRISPR / CAS9 and other technologies.
"We are at this stage right now, and in the animal testing group we are injecting them with chemical compounds and then studying their behavior to monitor the improvement of their memory," Khatib said. We examine their brains to make sure that these compounds are broken down into brains of patients with Alzheimer's disease, beta-amyloid and others.
Dr. Al-Khatib shared the results of his research
"The results obtained so far on laboratory neurons and animal models are excellent and promising, so we have officially registered these compounds as a patent at WIPO, the world organization of protection of intellectual property for individuals (established in Geneva) .These compounds are coming soon for the next phase: clinical trials on humans, everything goes well, we will start to manufacture vehicles in the form of drugs and We anticipate this process will take several years. "
"Our ambition is to be able to develop future applications for vehicles, to reach a pharmaceutical industry used to treat Alzheimer's disease, if the drugs succeed in clinical trials on humans, then the drug will be widely used by all the patients of the world. "
Retinoic acid is very important for humans at all stages of life, as well as for brain development and normal functioning, which prompted Khatib and his research team to study the relationship between Retinoic acid and Alzheimer's disease, pointing out that the material was weak in animal models infected with the disease by hybridization, I tried to strengthen the substance and use it to Therapeutic way against Alzheimer's disease, working with a team of chemists from another university in the UK, to help them design chemical compounds.
Khatib aspires to continue his development of neuroscience and research in his home country, Palestine.
CV
Marwan al-Khatib, a doctor and researcher in applied neuroscience, who was granted a patent in 2017, is continuing to work with his research team to develop compounds used in RAR-related cases. The university awarded him a three-year bachelor's degree instead of four years and a rate of 3.95 out of 4; it is the first in the field of biology and biotechnology and the third university. And the honor of the Palestinian Prime Minister after obtaining a master's degree at the rate of 4 out of 4 and being the first university. And honored by the Palestinian Higher Council for its creativity and excellence in granting a shield of creativity and excellence, as well as by its generosity to the Jenin Governorate to fulfill its humanitarian mission of carrying the name of the State of Palestine and its excellence in the field of research.
Edit مهند الحميدي
[ad_2]
Source link
